Navigate Regulations to Accelerate Next Generation Cell Therapies to Clinic, Streamline Manufacturing to Reduce CoGs & Reinvigorate Investment to Develop Safe, Cost-Effective & Commercially Viable Cell Therapies in Asia 

Welcome to the 3rd CAR-TCR: Cell Therapy Summit Asia

In the dynamic landscape of cell therapy development, Asia is emerging as a powerhouse, witnessing a remarkable surge in investment and receiving strong regulatory support as companies rapidly progress in clinical and commercial development. Against this backdrop of rapid progress, the 3rd CAR-TCR: Cell Therapy Summit Asia stands as the pivotal gathering for industry players across the APAC region looking to capitalize on Asia's cell therapy boom.  

We have collaborated with the most influential thought leaders from Biosyngen, SCG Cell Therapy, regulatory bodies including HSA and venture capitalists from across Vietnam, China, Singapore, Taiwan, India and Australia to uncover and share critical end-to-end lessons learned across autoimmune diseases, liquid and solid tumor indications to enable you to fast-track your clinical pipelines.  

With a primary focus on the evolving regulatory space across Asia, the drive to expedite next-generation cell therapies to clinical fruition, optimizing manufacturing processes to reduce costs, reigniting investment interest and streamlining commercial access to safe cell therapies, this dedicated meeting strives to accelerate your promising discoveries from bench to bedside. 

CAR-T Asia Email Banners (4)

2024 Expert Speakers









Must-Attend Sessions

Immuneel Logo

Developing robust strategies to attract investments, forecast supply and demand and explore patient access for successful cell therapy commercialization and market access  

FONSUN Kite Logo

Discovering best practices to achieve regulatory approvals and the importance of fostering collaborations in the community to boost cutting-edge cancer treatments

JW Therapeutics Logo

Latest Phase 1 Autoimmune clinical trial data using CD19 CAR-T to treat SLE patients, focusing on safety, tolerability, and determining the recommended Phase 2 dose  

About CAR-TCR Series

For over nine years, the CAR-TCR Summit Series by Hanson Wade has stood as a pillar of knowledge-sharing in the field of cell therapy. The series is committed to delivering an exclusive platform to unite the community and explore the key challenges to your industry, guided by global thought leaders in each discipline.

Dedicated to the development of safe, clinically effective and globally accessible therapies, the series is an unrivalled opportunity to gather with other cell therapy experts.

From next-generation development to supply chain and logistics, and exploring challenges specific to each function and indication, we create these forums to deliver value and in-depth learnings across the development pipeline, on a global stage.

Bristol Myers Squibb Logo

‘The conference was well put together and it was very insightful to listen to the different experiences from other industry members as well as the advancements in the science and technology’
– Senior Manager, MSAT (2023 CAR-TCR Boston Attendee)

Bristol Myers Squibb Logo
Bio Bridge Logo

’The quality of the talks and the things that I learned at the event were very helpful. I really appreciated the lengthy breaks that gave us time to connect with colleagues and continue meaningful discussions’
– Senior Vice President (2023 CAR-TCR Boston Attendee)

Bio Bridge Logo